Selecta Biosciences (NASDAQ:SELB) will be posting its quarterly earnings results before the market opens on Thursday, August 8th. Analysts expect Selecta Biosciences to post earnings of ($0.34) per share for the quarter.
Selecta Biosciences (NASDAQ:SELB) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.06. The firm had revenue of $0.01 million for the quarter. On average, analysts expect Selecta Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
NASDAQ SELB traded up $0.06 during trading on Tuesday, hitting $1.86. 2,915 shares of the stock traded hands, compared to its average volume of 180,489. The firm has a market capitalization of $82.41 million, a P/E ratio of -0.63 and a beta of 1.17. Selecta Biosciences has a 12-month low of $1.41 and a 12-month high of $16.55. The company has a 50-day moving average of $1.80.
Several equities research analysts have recently issued reports on SELB shares. Zacks Investment Research lowered Selecta Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 11th. ValuEngine raised Selecta Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Mizuho reissued a “buy” rating and set a $4.00 price target on shares of Selecta Biosciences in a research note on Friday, May 10th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $8.04.
About Selecta Biosciences
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.